EGFR Mutations in Plasma Linked to Patient Outcomes in Non-Small Cell Lung Cancer

Strategic Insights -

Researchers at the University of California, Davis Cancer Center have discovered that EGFR mutations detected in plasma are associated with patient outcomes in erlotinib plus docetaxel-treated non-small cell lung cancer. The study, published in the Journal of Thoracic Oncology, found that activating mutations in the epidermal growth factor receptor (EGFR) are linked to enhanced response to EGFR tyrosine kinase inhibitors in non-small cell lung cancer (NSCLC). In contrast, KRAS mutations are associated with poor patient outcomes.

Key Takeaways:

  • EGFR mutations were detected in 20% of patients (10 out of 49) in the study, with six patients having single activating mutations in EGFR.
  • Patients with EGFR mutations had improved progression-free survival (median, 18.3 months) compared to those without mutations (median, 3.9 months; p=0.008).
  • The addition of docetaxel did not diminish the efficacy of erlotinib against patients with EGFR activating mutations.
  • KRAS mutations were detected in two patients, both of whom had rapid progressive disease.
  • Activating EGFR mutations detected in shed DNA in plasma are significantly associated with favorable outcomes in patients with advanced NSCLC receiving docetaxel plus intercalated erlotinib.

Statistics:

  • 20% of patients in the study had EGFR mutations detected in plasma DNA.
  • 6 out of 49 patients had single activating mutations in EGFR.
  • Patients with EGFR mutations had a median progression-free survival of 18.3 months.
  • Patients without EGFR mutations had a median progression-free survival of 3.9 months.
  • The KRAS mutations were detected in 2 out of 49 patients.

Sources:

  • Mack, P., et al. (2009). EGFR mutations detected in plasma are associated with patient outcomes in erlotinib plus docetaxel-treated non-small cell lung cancer. Journal of Thoracic Oncology, 4(12), 1466-1472.